ImmunoForge is focused on the development of innovative pharmaceutical solutions utilizing its proprietary ELP (Elastin-Like Polypeptide) platform technology. This technology is designed to enhance the pharmacokinetics of therapeutic agents by extending their half-life, which can lead to improved efficacy and reduced dosing frequency for patients. The company’s pipeline includes several drug candidates, such as Froniglutide and Pemziviptadil, which are being developed to address various medical conditions through this advanced platform.

The ELP platform technology not only supports the development of long-acting therapeutics but also demonstrates versatility in creating a range of drug formulations. ImmunoForge's commitment to leveraging this technology is evident in its collaborations and research agreements, which aim to further enhance the capabilities of its drug development processes. The company has received recognition from regulatory bodies, including the U.S. FDA, for its innovative approaches, underscoring its potential impact in the pharmaceutical industry.

South Korea

ImmunoForge is a biopharmaceutical company that specializes in developing targeted cancer agents for conditions like sarcopenia and rare mutations including BCR-ABL, T315I, RET, and FGFR4.

Cardiovascular Diseases

Digestive System Diseases

Hematologic Diseases

Musculoskeletal Diseases

Nervous System Diseases

Skin Diseases

ImmunoForge

Dermatomyositis

Polymyositis

PF1801

Biologics

Peptide Therapies

Small Molecule Pharmaceuticals

Therapeutic

ImmunoForge

Company Details